The latest biotechnology news | Bio News
non-opiod IRA

Development of non-opioid pain medicines threated by IRA’s ‘pill penalty’

The search for safer, effective replacements for opioids is a critical public health ...
Read More
AI biotech

BIF 2024: AI experts discuss use cases, benefits, ROI

“All of us have been paying attention and seeing the ‘AI high’ for ...
Read More
BIO Investor forum IPO

BIO Investor Forum panel breaks down when, what, and why of IPOs

Biotech firms weighing an initial public offering (IPO) must consider timing, interest in ...
Read More
BIO's Crystal Kuntz at the 2024 BIO Investor Forum in San Francisco

BIF 2024: ‘The IRA really disrupted how we think’

The Inflation Reduction Act (IRA) has been top of mind for many in ...
Read More
Senior couple medicating at home with medical prescription

As Medicare open enrollment nears, seniors will face difficult choices despite CMS’ rosy assessment

Prescription drug coverage in Medicare will see sweeping changes – for both health ...
Read More
IMG_7356

BIO Investor Forum opens with encouraging news on financing

The tide has been rising in biotech investment in 2024—though it has not ...
Read More
Save with Avantor and BIO Business Solutions

EDITORS' CHOICE

IMG_7356

BIO Investor Forum opens with encouraging news on financing

The tide has been rising in biotech investment in 2024—though it has not lifted all boats equally. While the volume of investment improved in the ...
Read More

LATEST NEWS

BIO's View

Development of non-opioid pain medicines threated by IRA’s ‘pill penalty’

The search for safer, effective replacements for opioids is a critical public health priority, but that effort is being undermined by the Inflation Reduction Act ...
BIO Events

BIF 2024: AI experts discuss use cases, benefits, ROI

“All of us have been paying attention and seeing the ‘AI high’ for the last several years,” said Ruchita Sinha, MBA, General Partner at AV8 ...
BIO Events

BIO Investor Forum panel breaks down when, what, and why of IPOs

Biotech firms weighing an initial public offering (IPO) must consider timing, interest in their product, the macro environment—and whether they really need all the headaches, ...
BIO Events

BIF 2024: ‘The IRA really disrupted how we think’

The Inflation Reduction Act (IRA) has been top of mind for many in the biotech industry. The first round of price negotiations and the impending ...
BIO's View

As Medicare open enrollment nears, seniors will face difficult choices despite CMS’ rosy assessment

Prescription drug coverage in Medicare will see sweeping changes – for both health plans and for the millions of American seniors they serve – despite ...

Welcome, John F. Crowley!

Get to know John F. Crowley, the new President and CEO of the Biotechnology Innovation Organization (BIO), in our exclusive interview.

AGRICULTURE

Climate Change

BIO priorities

What to know about BIO’s 7 Core Strategic Priorities

With the 118th Congress wrapping up in a few months, the Biotechnology Innovation Organization (BIO) continues its work to improve ...
Read More

Federal Policy

State Policy

International

Bio's View

Scroll to Top